US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...